Collegium Pharmaceutical Q2 Adj EPS $1.26 Beats $1.22 Estimate, Sales $135.55M Miss $137.98M Estimate
Portfolio Pulse from bharat@benzinga.com
Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 earnings of $1.26 per share, beating the analyst consensus estimate of $1.22 by 3.28%. This is a 281.82% increase from the same period last year. However, the company's quarterly sales of $135.55 million missed the analyst consensus estimate of $137.98 million by 1.76%, though it's a 9.71% increase from last year.
August 04, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Collegium Pharmaceutical's Q2 earnings beat estimates but sales missed, which may have mixed effects on the stock.
While the earnings beat is positive for the stock, the sales miss could offset this positivity. The net effect on the stock is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100